MX2018014298A - Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida. - Google Patents

Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.

Info

Publication number
MX2018014298A
MX2018014298A MX2018014298A MX2018014298A MX2018014298A MX 2018014298 A MX2018014298 A MX 2018014298A MX 2018014298 A MX2018014298 A MX 2018014298A MX 2018014298 A MX2018014298 A MX 2018014298A MX 2018014298 A MX2018014298 A MX 2018014298A
Authority
MX
Mexico
Prior art keywords
indazol
ylamino
pyran
difluoro
tetrahydro
Prior art date
Application number
MX2018014298A
Other languages
English (en)
Inventor
Candiani Ilaria
OTTAIANO Giovanni
Tomasi Attilio
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of MX2018014298A publication Critical patent/MX2018014298A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se refiere a una nueva forma cristalina de N-[5-(3,5-difluoro-bencilo)-1h-indazol-3-il]-4-(4-metilo-piperazi na-1-il)-2-(tetrahidro-pirano-4-ilamino)-benzamida, al proceso para su preparación, su utilidad en el tratamiento de enfermedades causadas por la actividad de la proteína quinasa no regulada y a las composiciones farmacéuticas que la contienen.
MX2018014298A 2016-05-24 2017-05-18 Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida. MX2018014298A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662340797P 2016-05-24 2016-05-24
PCT/EP2017/061919 WO2017202674A1 (en) 2016-05-24 2017-05-18 New crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide

Publications (1)

Publication Number Publication Date
MX2018014298A true MX2018014298A (es) 2019-03-14

Family

ID=58709993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014298A MX2018014298A (es) 2016-05-24 2017-05-18 Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.

Country Status (14)

Country Link
US (2) US10738037B2 (es)
EP (2) EP3464276B1 (es)
JP (2) JP7094228B2 (es)
KR (1) KR102441736B1 (es)
CN (1) CN109153669B (es)
AU (1) AU2017271458B2 (es)
BR (1) BR112018073951A2 (es)
CA (1) CA3024208C (es)
ES (1) ES2899953T3 (es)
HK (1) HK1259405A1 (es)
IL (1) IL263004B (es)
MX (1) MX2018014298A (es)
PL (1) PL3464276T3 (es)
WO (1) WO2017202674A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3464276T3 (pl) * 2016-05-24 2022-04-04 Nerviano Medical Sciences S.R.L. Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu
EP4003309A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG New pharmaceutical formulation
US20220372024A1 (en) * 2019-11-01 2022-11-24 Johnson Matthey Public Limited Company Crystalline forms of entrectinib
CN113024521B (zh) * 2019-12-09 2023-01-17 武汉九州钰民医药科技有限公司 一种制备恩曲替尼的方法
CN111171009B (zh) * 2020-01-10 2022-07-12 安礼特（上海）医药科技有限公司 恩曲替尼晶型及其制备方法
CN113801062B (zh) * 2020-06-15 2023-05-26 沈阳药科大学 3-氨基-5-(3,5-二氟苄基)-1h-吲唑的制备方法
CN112336723B (zh) * 2020-12-11 2023-09-26 江南大学 制备用于降低trpv4与nox2耦联度的药物的方法
WO2022166647A1 (zh) * 2021-02-03 2022-08-11 齐鲁制药有限公司 恩曲替尼晶型及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2176231T1 (sl) * 2007-07-20 2017-01-31 Nerviano Medical Sciences S.R.L. Substituirani indazolni derivati, aktivni kot kinazni inhibitorji
BR112014028841B1 (pt) * 2012-05-23 2021-01-12 Nerviano Medical Sciences S.R.L. Formas cristalinas 1 e 2, composição farmacêutica, uso da forma cristalina 1 para o tratamento de um estado de doença tratável pela inibição de alk e processo para a preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metilpiperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)- benzamida
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
PL3464276T3 (pl) 2016-05-24 2022-04-04 Nerviano Medical Sciences S.R.L. Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu

Also Published As

Publication number Publication date
PL3464276T3 (pl) 2022-04-04
AU2017271458B2 (en) 2020-11-26
AU2017271458A1 (en) 2019-01-17
BR112018073951A2 (pt) 2019-02-26
CA3024208A1 (en) 2017-11-30
US20200325122A1 (en) 2020-10-15
EP3967689A1 (en) 2022-03-16
JP7154271B2 (ja) 2022-10-17
EP3464276A1 (en) 2019-04-10
HK1259405A1 (zh) 2019-11-29
EP3464276B1 (en) 2021-09-01
JP2019516749A (ja) 2019-06-20
ES2899953T3 (es) 2022-03-15
JP2021042213A (ja) 2021-03-18
CA3024208C (en) 2022-07-26
CN109153669B (zh) 2021-12-24
WO2017202674A1 (en) 2017-11-30
KR20190005236A (ko) 2019-01-15
CN109153669A (zh) 2019-01-04
US20190169173A1 (en) 2019-06-06
JP7094228B2 (ja) 2022-07-01
US10738037B2 (en) 2020-08-11
IL263004A (en) 2018-12-31
US11091469B2 (en) 2021-08-17
KR102441736B1 (ko) 2022-09-13
IL263004B (en) 2022-04-01

Similar Documents

Publication Publication Date Title
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
MX2014013924A (es) Proceso para la preparacion de n- [5- (3,5-difluoro-bencil) -1h-indazol-3-il] -4- (4-metil-piperazin-1-il) -2- (tetrahidro-piran-4-ilamino) -benzamida.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
GEP20207147B (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
TN2019000281A1 (en) Ferroportin-inhibitor salts
SA515360007B1 (ar) مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk)
EA201690752A1 (ru) Ингибиторы g12c kras
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
TN2015000429A1 (en) 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
NZ738836A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
PH12015502110A1 (en) Crystalline forms of tyrosine kinase inhibitors and their salts
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
WO2017168454A3 (en) Novel compounds as btk inhibitors